2
RESEARCH METHODOLOGY
35
5
MARKET OVERVIEW
Rising demand for radioligand therapies driven by regulatory approvals and technological advancements.
61
5.2.1.1
INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS
5.2.1.2
MANUFACTURING SCALE-UP OF LU-177
5.2.1.3
RISING ADOPTION OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND SOMATOSTATIN RECEPTOR PET IMAGING
5.2.1.4
EXPANDING REIMBURSEMENT COVERAGE
5.2.2.1
ISOTOPE SUPPLY SCARCITY
5.2.2.2
STRINGENT REGULATORY REQUIREMENTS
5.2.2.3
LOGISTICAL HURDLES AND HALF-LIFE CONSTRAINTS
5.2.3.1
ADVANCEMENTS IN ALPHA THERAPIES
5.2.3.2
EXPANSION OF RADIOLIGAND THERAPY INTO EARLIER-LINE AND ADJUVANT SETTINGS
5.2.3.3
COMBINATION REGIMENS INTEGRATING RADIOLIGAND THERAPY
5.2.4.1
REACTOR OUTAGES AND GEOPOLITICAL RISKS
5.2.4.2
GROWING COMPETITION FROM ALTERNATIVE MODALITIES
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4.1
INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
5.4.2
INDICATIVE PRICING ANALYSIS, BY REGION
5.7
INVESTMENT AND FUNDING SCENARIO
5.8.1.1
BETA-EMITTING THERAPEUTIC RADIONUCLIDES
5.8.1.2
ALPHA-EMITTING THERAPEUTIC RADIONUCLIDES
5.8.1.3
TARGETING LIGANDS
5.8.1.4
MONOCLONAL ANTIBODY-DIRECTED RADIOTHERAPEUTICS
5.8.2
COMPLEMENTARY TECHNOLOGIES
5.8.2.1
SPECT/CT AND PET/CT
5.8.2.2
ALTERNATIVE ISOTOPES
5.8.3
ADJACENT TECHNOLOGIES
5.8.3.1
ANTIBODY DRUG CONJUGATES
5.8.3.2
BISPECIFIC ANTIBODIES
5.9
KEY CONFERENCES AND EVENTS, 2025–2027
5.10
REGULATORY LANDSCAPE
5.10.1
REGULATORY ANALYSIS
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11
PORTER’S FIVE FORCES ANALYSIS
5.11.1
BARGAINING POWER OF SUPPLIERS
5.11.2
BARGAINING POWER OF BUYERS
5.11.3
THREAT OF NEW ENTRANTS
5.11.4
THREAT OF SUBSTITUTES
5.11.5
INTENSITY OF COMPETITIVE RIVALRY
5.12
KEY STAKEHOLDERS AND BUYING PROCESS
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.13
MACROECONOMICS INDICATORS
5.13.1
HEALTHCARE EXPENDITURE TRENDS
5.13.2
GLOBAL CANCER BURDEN
5.15
UNMET NEEDS AND WHITE SPACES
5.16
IMPACT OF AI/GEN AI ON RADIOLIGAND THERAPY MARKET
5.16.2
MARKET POTENTIAL OF AI IN RADIOLIGAND THERAPY APPLICATIONS
5.17
IMPACT OF 2025 US TARIFF
5.17.3
PRICE IMPACT ANALYSIS
5.17.4
IMPACT ON COUNTRY/REGION
5.17.4.4
REST OF THE WORLD
5.17.5
IMPACT ON MANUFACTURING INDUSTRY
6
RADIOLIGAND THERAPY MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 78 Data Tables
97
6.2
LUTETIUM-177 VIPIVOTIDE TETRAXETAN
6.2.1
BROADER REGULATORY ACCEPTANCE AND EXPANDING PAYER COVERAGE TO AID GROWTH
6.3
LUTETIUM-177 DOTATATE
6.3.1
INCREASING RECOGNITION OF LUTETIUM-177 DOTATATE IN TREATING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO BOOST MARKET
6.4
RADIUM-223 DICHLORIDE
6.4.1
INCREASING ADOPTION OF RADIUM-223 DICHLORIDE IN EMERGING MARKETS TO STIMULATE GROWTH
6.5.1
STRONG PHASE III CLINICAL VALIDATION AND STRATEGIC COMMERCIALIZATION PARTNERSHIPS TO SPUR GROWH
6.6.1
POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO BOLSTER GROWTH
6.7.1
EARLY RESPONSE DATA AND SAFETY REASSURANCE TO AMPLIFY GROWTH
6.8.1
FAVORABLE DOSIMETRY AND SAFETY PROFILES TO SUSTAIN GROWTH
6.9.1
SIMPLIFIED DOSING REGIMEN AND FAVORABLE TOLERABILITY TO DRIVE MARKET
6.10
ALPHAMEDIX ( ²¹²PB-DOTAMTATE)
6.10.1
ROBUST EARLY-PHASE EFFICACY AND STRONG COMMERCIALIZATION TO SUPPORT GROWTH
6.11.1
ENHANCED LESION UPTAKE & RETENTION AND FAVORABLE TOLERABILITY PROFILE TO FOSTER GROWTH
7
RADIOLIGAND THERAPY MARKET, BY TARGET
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 22 Data Tables
136
7.2
PROSTATE-SPECIFIC MEMBRANE ANTIGEN
7.2.1
STRONG BIOLOGICAL RATIONALE, ROBUST CLINICAL OUTCOMES, AND RAPID SCALING OF GLOBAL SUPPLY CHAINS TO PROMOTE GROWTH
7.3
SOMATOSTATIN RECEPTOR
7.3.1
PROVEN EFFICACY IN TREATING NEUROENDOCRINE TUMORS TO EXPEDITE GROWTH
8
RADIOLIGAND THERAPY MARKET, BY INDICATION
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 22 Data Tables
148
8.2.1
EXPANDING TREATMENT POPULATIONS AND CLINICAL VALIDATION TO ENCOURAGE GROWTH
8.3
NEUROENDOCRINE TUMORS
8.3.1
REGULATORY ADVANCEMENTS AND STRATEGIC INDUSTRY MOVES TO FACILITATE GROWTH
9
RADIOLIGAND THERAPY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 22 Data Tables
160
9.2
TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS
9.2.1
ADVANCED TREATMENT DELIVERY AND CLINICAL TRIAL CAPABILITIES TO CONTRIBUTE TO GROWTH
9.3
SPECIALIZED NUCLEAR MEDICINE CENTERS
9.3.1
HIGHLY TRAINED PERSONNEL AND TARGETED FACILITIES TO ACCELERATE GROWTH
10
RADIOLIGAND THERAPY MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 125 Data Tables.
173
10.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2.1
ROBUST ECOSYSTEM OF BIOTECH INNOVATION AND STRONG ACADEMIC-INDUSTRY COLLABORATION TO SPUR GROWTH.
10.2.3.1
GROWING CLINICAL TRIAL MOMENTUM TO DRIVE MARKET
10.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2.1
STRONG CLINICAL ADVANCEMENTS AND ACTIVE INDUSTRY PARTNERSHIPS TO FOSTER GROWTH.
10.3.3.1
GROWING EFFORTS FOR DECENTRALIZED ACCESS AND INNOVATIONS TO BOOST MARKET
10.3.4.1
STRONG NUCLEAR MEDICINE MANUFACTURING AND ISOTOPE SUPPLY FOUNDATION TO BOLSTER GROWTH
10.3.5.1
RISING PRECLINICAL EXPLORATION AND EARLY DISCOVERY STAGES TO STIMULATE GROWTH
10.3.6.1
ESTABLISHED NUCLEAR-MEDICINE DEPARTMENTS AND AUTHORIZED RADIOPHARMACY FRAMEWORKS TO AID GROWTH
10.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2.1
FAVORABLE REGULATORY REFORMS AND EXPANDING HOSPITAL-BASED NUCLEAR MEDICINE CAPABILITIES TO AMPLIFY GROWTH
10.4.3.1
ACADEMIC EXCELLENCE, MANUFACTURING EXPANSION, AND SUPPORTIVE REGULATION TO CONTRIBUTE TO GROWTH
10.4.4.1
LOWER TRIAL COSTS AND SKILLED MEDICAL PROFESSIONALS TO ACCELERATE GROWTH
10.4.5.1
GROWING EMPHASIS ON NUCLEAR MEDICINE INNOVATION TO PROPEL MARKET
10.4.6.1
NEED TO MAINTAIN HIGH STANDARDS OF QUALITY, COMPLIANCE, AND INNOVATION TO FACILITATE GROWTH
10.4.7
REST OF ASIA PACIFIC
10.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2.1
FAVORABLE EDUCATIONAL INITIATIVES AND EXPANDING BIOPHARMA INFRASTRUCTURE TO PROMOTE GROWTH
10.5.3.1
GROWING CYCLOTRON CAPACITY TO FUEL MARKET
10.5.4
REST OF LATIN AMERICA
10.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
10.6.3.1
GROWING INITIATIVES FOR HEALTHCARE AND LIFE SCIENCES SECTORS TO DRIVE MARKET
10.6.4.1
EMERGING BIOTECHNOLOGY SECTOR TO INTENSIFY GROWTH
10.6.5
REST OF GCC COUNTRIES
10.6.6
REST OF MIDDLE EAST
10.7.1
ENHANCED CLINICAL TRIAL ECOSYSTEM AND REGULATORY REFORMS TO AID GROWTH
10.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
11
COMPETITIVE LANDSCAPE
Discover strategic maneuvers propelling top players to dominate market share and valuations by 2030.
242
11.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.4
REVENUE ANALYSIS, 2028–2030
11.5
MARKET SHARE ANALYSIS, 2030
11.6
COMPANY VALUATION AND FINANCIAL METRICS
11.7
BRAND/PRODUCT COMPARISON
11.8
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.8.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.8.5.1
REGION FOOTPRINT
11.8.5.2
TARGET FOOTPRINT
11.8.5.3
INDICATION FOOTPRINT
11.9
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.9.1
PROGRESSIVE COMPANIES
11.9.2
RESPONSIVE COMPANIES
11.9.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.9.5.1
DETAILED LIST OF KEY STARTUPS/SMES
11.9.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.10
COMPETITIVE SCENARIO
11.10.1
PRODUCT LAUNCHES AND APPROVALS
12
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
260
12.1.1.1
BUSINESS OVERVIEW
12.1.1.2
PRODUCTS OFFERED
12.1.1.3
PRODUCTS IN PIPELINE
12.1.1.4
RECENT DEVELOPMENTS
12.1.4
ELI LILLY AND COMPANY
12.1.6
PROGENICS PHARMACEUTICALS INC. (LANTHEUS)
12.1.7
ARICEUM THERAPEUTICS
12.1.8
TELIX PHARMACEUTICALS
12.1.9
ITM ISOTOPE TECHNOLOGIES
12.1.10
CONVERGENT THERAPEUTICS, INC.
12.1.12
ACTINIUM PHARMACEUTICALS, INC.
12.1.13
PERSPECTIVE THERAPEUTICS, INC.
12.1.14
CLARITY PHARMACEUTICALS
12.1.15
RADIOPHARM THERANOSTICS LTD.
12.2.2
RATIO THERAPEUTICS
12.2.3
NORIA THERAPEUTICS
12.2.6
ECKERT & ZIEGLER RADIOPHARMA
12.2.7
NORTHSTAR MEDICAL RADIOISOTOPES, LLC
12.2.10
NTP RADIOISOTOPES
13.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3
CUSTOMIZATION OPTIONS
TABLE 1
RADIOLIGAND THERAPY MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 3
RADIOLIGAND THERAPY MARKET: RISK ANALYSIS
TABLE 4
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FOR RADIOPHARMACEUTICAL MOLECULES BY REGION, 2023–2030 (USD BILLION)
TABLE 5
RADIOLIGAND THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 6
INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024
TABLE 7
INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY REGION, 2024
TABLE 8
RADIOLIGAND THERAPY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 9
RADIOLIGAND THERAPY MARKET: KEY CONFERENCES AND EVENTS, 2025–2027
TABLE 10
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 15
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND THERAPY PRODUCTS (%)
TABLE 16
KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY, BY END USER
TABLE 17
HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP)
TABLE 18
US: CANCER INCIDENCE, BY STATE, 2024
TABLE 19
RADIOLIGAND THERAPY PRODUCTS IN CLINICAL PIPELINE, 2025–2032
TABLE 20
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 21
RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 22
RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023–2035 (USD MILLION)
TABLE 23
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 24
EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 25
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 26
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 27
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023–2035 (USD MILLION)
TABLE 28
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 29
RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION)
TABLE 30
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 31
EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 32
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 33
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 34
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION)
TABLE 35
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 36
RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION)
TABLE 37
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 38
EUROPE: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 39
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 40
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 41
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION)
TABLE 42
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 43
RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION, 2023–2035 (USD MILLION)
TABLE 44
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 45
EUROPE: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 46
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 47
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 48
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION, 2023–2035 (USD MILLION)
TABLE 49
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 50
RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY REGION, 2023–2035 (USD MILLION)
TABLE 51
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 52
EUROPE: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 53
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 54
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617,0 BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 55
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY REGION, 2023–2035 (USD MILLION)
TABLE 56
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 57
RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION, 2023–2035 (USD MILLION)
TABLE 58
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 59
EUROPE: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 60
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 61
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 62
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION, 2023–2035 (USD MILLION)
TABLE 63
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 64
RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION)
TABLE 65
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 66
EUROPE: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 67
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 68
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 69
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION)
TABLE 70
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 71
RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION)
TABLE 72
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 73
EUROPE: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 74
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 75
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 76
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION)
TABLE 77
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 78
RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION)
TABLE 79
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 80
EUROPE: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 81
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 82
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 83
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION)
TABLE 84
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 85
RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION)
TABLE 86
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 87
EUROPE: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 88
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 89
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 90
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION)
TABLE 91
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 92
RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION)
TABLE 93
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 94
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 95
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 96
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 97
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION)
TABLE 98
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 99
RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 100
RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION)
TABLE 101
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 102
EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 103
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 104
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 105
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION)
TABLE 106
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 107
RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION)
TABLE 108
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 109
EUROPE: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 110
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 111
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 112
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION)
TABLE 113
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 114
RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)
TABLE 115
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 116
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 117
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 118
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 119
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)
TABLE 120
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)
TABLE 121
RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 122
RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION)
TABLE 123
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 124
EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 125
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 126
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 127
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION)
TABLE 128
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 129
RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION)
TABLE 130
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 131
EUROPE: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 132
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 133
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 134
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION)
TABLE 135
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 136
RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION)
TABLE 137
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 138
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 139
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 140
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 141
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION)
TABLE 142
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 143
RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 144
RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION)
TABLE 145
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 146
EUROPE: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 147
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 148
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 149
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION)
TABLE 150
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 151
RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION)
TABLE 152
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 153
EUROPE: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 154
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 155
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 156
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION)
TABLE 157
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 158
RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION)
TABLE 159
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 160
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 161
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 162
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 163
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION)
TABLE 164
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 165
RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION)
TABLE 166
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 167
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 168
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 169
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 170
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 171
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 172
US: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 173
US: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 174
US: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 175
US: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 176
CANADA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 177
CANADA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 178
CANADA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 179
CANADA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 180
EUROPE: KEY MACROECONOMIC INDICATORS
TABLE 181
EUROPE: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 182
EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 183
EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 184
EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 185
EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 186
GERMANY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 187
GERMANY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 188
GERMANY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 189
GERMANY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 190
UK: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 191
UK: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 192
UK: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 193
UK: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 194
FRANCE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 195
FRANCE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 196
FRANCE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 197
FRANCE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 198
ITALY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 199
ITALY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 200
ITALY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 201
ITALY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 202
SPAIN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 203
SPAIN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 204
SPAIN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 205
SPAIN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 206
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 207
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 208
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 209
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 210
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
TABLE 211
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 212
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 213
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 214
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 215
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 216
CHINA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 217
CHINA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 218
CHINA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 219
CHINA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 220
JAPAN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 221
JAPAN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 222
JAPAN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 223
JAPAN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 224
INDIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 225
INDIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 226
INDIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 227
INDIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 228
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 229
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 230
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 231
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 232
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 233
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 234
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 235
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 236
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 237
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 238
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 239
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 240
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 241
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 242
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 243
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 244
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 245
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 246
BRAZIL: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 247
BRAZIL: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 248
BRAZIL: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 249
BRAZIL: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 250
MEXICO: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 251
MEXICO: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 252
MEXICO: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 253
MEXICO: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 254
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 255
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 256
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 257
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 258
MIDDLE EAST: KEY MACROECONOMIC INDICATORS
TABLE 259
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION)
TABLE 260
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 261
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 262
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 263
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 264
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
TABLE 265
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 266
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 267
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 268
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 269
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 270
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 271
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 272
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 273
UAE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 274
UAE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 275
UAE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 276
UAE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 277
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 278
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 279
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 280
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 281
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 282
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 283
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 284
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 285
AFRICA: KEY MACROECONOMIC INDICATORS
TABLE 286
AFRICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
TABLE 287
AFRICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
TABLE 288
AFRICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
TABLE 289
AFRICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
TABLE 290
OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOLIGAND THERAPY MARKET, 2023–2025
TABLE 291
RADIOLIGAND THERAPY MARKET: DEGREE OF COMPETITION
TABLE 292
RADIOLIGAND THERAPY MARKET: REGION FOOTPRINT
TABLE 293
RADIOLIGAND THERAPY MARKET: TARGET FOOTPRINT
TABLE 294
RADIOLIGAND THERAPY MARKET: INDICATION FOOTPRINT
TABLE 295
RADIOLIGAND THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 296
RADIOLIGAND THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 297
RADIOLIGAND THERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
TABLE 298
RADIOLIGAND THERAPY MARKET: DEALS, JANUARY 2022–AUGUST 2025
TABLE 299
RADIOLIGAND THERAPY MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 300
NOVARTIS AG: COMPANY OVERVIEW
TABLE 301
NOVARTIS AG: PRODUCTS OFFERED
TABLE 302
NOVARTIS AG: PRODUCTS IN PIPELINE
TABLE 303
NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
TABLE 304
NOVARTIS AG: DEALS, JANUARY 2022–AUGUST 2025
TABLE 305
NOVARTIS AG: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 306
BAYER AG: COMPANY OVERVIEW
TABLE 307
BAYER AG: PRODUCTS OFFERED
TABLE 308
BAYER AG: DEALS, JANUARY 2022–AUGUST 2025
TABLE 309
BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
TABLE 310
CURIUM US LLC: COMPANY OVERVIEW
TABLE 311
CURIUM US LLC: PRODUCTS IN PIPELINE
TABLE 312
CURIUM US LLC: DEALS, JANUARY 2022–AUGUST 2025
TABLE 313
ELI LILLY AND COMPANY: COMPANY OVERVIEW
TABLE 314
ELI LILLY AND COMPANY: PRODUCTS IN PIPELINE
TABLE 315
ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– AUGUST 2025
TABLE 316
ELI LILLY AND COMPANY: DEALS, JANUARY 2022–AUGUST 2025
TABLE 317
ASTRAZENECA: COMPANY OVERVIEW
TABLE 318
ASTRAZENECA: PRODUCTS IN PIPELINE
TABLE 319
ASTRAZENECA: DEALS, JANUARY 2022–AUGUST 2025
TABLE 320
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY OVERVIEW
TABLE 321
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): PRODUCTS IN PIPELINE
TABLE 322
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): DEALS, JANUARY 2022–AUGUST 2025
TABLE 323
ARICEUM THERAPEUTICS: COMPANY OVERVIEW
TABLE 324
ARICEUM THERAPEUTICS: PRODUCTS IN PIPELINE
TABLE 325
ARICEUM THERAPEUTICS: DEALS, JANUARY 2022–AUGUST 2025
TABLE 326
TELIX PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 327
TELIX PHARMACEUTICALS: PRODUCTS IN PIPELINE
TABLE 328
TELIX PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025
TABLE 329
TELIX PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 330
TELIX PHARMACEUTICAL: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
TABLE 331
ITM ISOTOPE TECHNOLOGIES: COMPANY OVERVIEW
TABLE 332
ITM ISOTOPE TECHNOLOGIES: PRODUCTS OFFERED
TABLE 333
ITM ISOTOPE TECHNOLOGIES: DEALS, JANUARY 2022–AUGUST 2025
TABLE 334
ITM ISOTOPE TECHNOLOGIES: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 335
CONVERGENT THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 336
CONVERGENT THERAPEUTICS, INC.: PRODUCTS IN PIPELINE
TABLE 337
CONVERGENT THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
TABLE 338
CONVERGENT THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025
TABLE 339
ORANO SA: COMPANY OVERVIEW
TABLE 340
ORANO SA: PRODUCTS IN PIPELINE
TABLE 341
ORANO SA: DEALS, JANUARY 2022–AUGUST 2025
TABLE 342
ORANO SA: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 343
ACTINIUM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 344
ACTINIUM PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE
TABLE 345
ACTINIUM PHARMACEUTICALS, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
TABLE 346
ACTINIUM PHARMACEUTICALS, INC.: DEALS, JANUARY 2022–AUGUST 2025
TABLE 347
PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 348
PERSPECTIVE THERAPEUTICS, INC.: PRODUCTS IN PIPELINE
TABLE 349
PERSPECTIVE THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025
TABLE 350
CLARITY PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 351
CLARITY PHARMACEUTICALS: PRODUCTS IN PIPELINE
TABLE 352
CLARITY PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025
TABLE 353
CLARITY PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
TABLE 354
RADIOPHARM THERANOSTICS LTD.: COMPANY OVERVIEW
TABLE 355
RADIOPHARM THERANOSTICS LTD.: PRODUCTS IN PIPELINE
TABLE 356
RADIOPHARM THERANOSTICS LTD.: DEALS, JANUARY 2022–AUGUST 2025
TABLE 357
ALPHA 9 ONCOLOGY: COMPANY OVERVIEW
TABLE 358
RATIO THERAPEUTICS: COMPANY OVERVIEW
TABLE 359
NORIA THERAPEUTICS: COMPANY OVERVIEW
TABLE 360
PRECIRIX: COMPANY OVERVIEW
TABLE 361
SOFIE: COMPANY OVERVIEW
TABLE 362
ECKERT & ZIEGLER RADIOPHARMA: COMPANY OVERVIEW
TABLE 363
NORTHSTAR MEDICAL RADIOISOTOPES, LLC: COMPANY OVERVIEW
TABLE 364
IRE- IRE ELIT: COMPANY OVERVIEW
TABLE 365
BWXT MEDICAL LTD.: COMPANY OVERVIEW
TABLE 366
NTP RADIOISOTOPES: COMPANY OVERVIEW
FIGURE 1
RADIOLIGAND THERAPY MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2
RADIOLIGAND THERAPY MARKET: YEARS CONSIDERED
FIGURE 3
RADIOLIGAND THERAPY MARKET: RESEARCH DESIGN
FIGURE 4
RADIOLIGAND THERAPY MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5
RADIOLIGAND THERAPY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 6
RADIOLIGAND THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 7
COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030
FIGURE 8
REVENUE SHARE ANALYSIS OF NOVARTIS, 2024
FIGURE 9
RADIOLIGAND THERAPY MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 10
RADIOLIGAND THERAPY MARKET: TOP-DOWN APPROACH
FIGURE 11
RADIOLIGAND THERAPY MARKET: CAGR PROJECTIONS
FIGURE 12
RADIOLIGAND THERAPY MARKET: DATA TRIANGULATION
FIGURE 13
RADIOLIGAND THERAPY MARKET: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
FIGURE 14
RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2025 VS. 2035 (USD MILLION)
FIGURE 15
RADIOLIGAND THERAPY MARKET, BY TARGET, 2025 VS. 2035 (USD MILLION)
FIGURE 16
RADIOLIGAND THERAPY MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION)
FIGURE 17
RADIOLIGAND THERAPY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION)
FIGURE 18
GEOGRAPHICAL SNAPSHOT OF RADIOLIGAND THERAPY MARKET
FIGURE 19
INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS TO DRIVE MARKET
FIGURE 20
LUTETIUM-177 VIPIVOTIDE TETRAXETAN SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2024
FIGURE 21
CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 22
DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
FIGURE 23
RADIOLIGAND THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24
NEW REVENUE POCKETS FOR PLAYERS IN RADIOLIGAND THERAPY MARKET
FIGURE 25
INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024
FIGURE 26
INDICATIVE PRICING ANALYSIS, BY REGION, 2024
FIGURE 27
RADIOLIGAND THERAPY MARKET: VALUE CHAIN ANALYSIS
FIGURE 28
RADIOLIGAND THERAPY MARKET: ECOSYSTEM ANALYSIS
FIGURE 29
RADIOLIGAND THERAPY MARKET: INVESTMENT AND FUNDING SCENARIO, 2023–2024
FIGURE 30
RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 31
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND THERAPY PRODUCTS
FIGURE 32
KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY PRODUCTS, BY END USER
FIGURE 33
RADIOLIGAND THERAPY MARKET: AI USE CASES
FIGURE 34
NORTH AMERICA: RADIOLIGAND THERAPY MARKET SNAPSHOT
FIGURE 35
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET SNAPSHOT
FIGURE 36
RADIOLIGAND THERAPY MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2028–2030 (USD MILLION)
FIGURE 37
RADIOLIGAND THERAPY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2030
FIGURE 38
EV/EBITDA OF KEY VENDORS
FIGURE 39
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 40
RADIOLIGAND THERAPY MARKET: BRAND/PRODUCT COMPARISON
FIGURE 41
RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 42
RADIOLIGAND THERAPY MARKET: COMPANY FOOTPRINT
FIGURE 43
RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 44
NOVARTIS AG: COMPANY SNAPSHOT (2024)
FIGURE 45
BAYER AG: COMPANY SNAPSHOT (2024)
FIGURE 46
ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)
FIGURE 47
ASTRAZENECA: COMPANY SNAPSHOT (2024)
FIGURE 48
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY SNAPSHOT (2024)
FIGURE 49
TELIX PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
FIGURE 50
ORANO SA: COMPANY SNAPSHOT (2024)
FIGURE 51
ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
FIGURE 52
CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
Growth opportunities and latent adjacency in Radioligand Therapy (RLT) Market